Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico.

MLA

Ponce-de-León, Samuel, et al. “Safety and Immunogenicity of a Live Recombinant Newcastle Disease Virus-Based COVID-19 Vaccine (Patria) Administered via the Intramuscular or Intranasal Route: Interim Results of a Non-Randomized Open Label Phase I Trial in Mexico.” MedRxiv : The Preprint Server for Health Sciences, Feb. 2022. EBSCOhost, https://doi.org/10.1101/2022.02.08.22270676.

APA

Ponce-de-León, S., Torres, M., Soto-Ramírez, L. E., Calva, J. J., Santillán-Doherty, P., Carranza-Salazar, D. E., Carreño, J. M., Carranza, C., Juárez, E., Carreto-Binaghi, L. E., Ramírez-Martínez, L., Paz-De la Rosa, G., Vigueras-Moreno, R., Ortiz-Stern, A., López-Vidal, Y., Macías, A. E., Torres-Flores, J., Rojas-Martínez, O., Suárez-Martínez, A., … Lozano-Dubernard, B. (2022). Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico. MedRxiv : The Preprint Server for Health Sciences. https://doi.org/10.1101/2022.02.08.22270676

Chicago

Ponce-de-León, Samuel, Martha Torres, Luis Enrique Soto-Ramírez, Juan José Calva, Patricio Santillán-Doherty, Dora Eugenia Carranza-Salazar, Juan Manuel Carreño, et al. 2022. “Safety and Immunogenicity of a Live Recombinant Newcastle Disease Virus-Based COVID-19 Vaccine (Patria) Administered via the Intramuscular or Intranasal Route: Interim Results of a Non-Randomized Open Label Phase I Trial in Mexico.” MedRxiv : The Preprint Server for Health Sciences, February. doi:10.1101/2022.02.08.22270676.